Navigation Links
Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
Date:5/20/2013

epend upon future circumstances that may or may not occur.

Examples of such forward looking statements include (but are not limited to) statements about expected benefits and risks associated with the Increased Offer; projections or expectations of profit attributable to shareholders; anticipated provisions or write-downs, economic profit, dividends, capital structure or any other financial items or ratios; statements of plans, objectives or goals of Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements about the future trends in interest rates, liquidity, foreign exchange rates, stock market levels and demographic trends and any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any "relevant securities" of Elan (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Royalty Pharma Announces Proposal To Acquire Elan
3. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
4. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
5. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
6. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
7. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
8. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
9. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... , CAMBRIDGE, Mass., July 20 ... biopharmaceutical company engaged in the discovery and development of drugs ... it has successfully completed a three-day proof-of-concept study of IDX184. ... guanosine nucleotide, for the treatment of HCV. , ...
... , CAPE TOWN, South Africa , ... 5(th) International AIDS Society Conference from ARTEN ( A tazanavir/ R ... mtricitabine [Truvada(R)] versus N evirapine). ARTEN is an open-label, multi-center ... study to directly compare the efficacy and safety of nevirapine and ...
Cached Medicine Technology:Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed 6
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 The short ... was created in honor of a true 9/11 hero, ... two film festivals including the 24 hours of Nuremberg International ... in Bangladesh. , Actress, screenwriter and director Luciana ... produce this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... When head lice hits a home or school, parents ... rid of it while keeping it from taking over the ... the solution right in their neighborhood: Lice Troopers . ... full spectrum head lice screening and treatment services to families ... Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- Overeating is common ... you eat in moderation, an expert says. "Don,t arrive ... up calories if you know you,ll be attending a party, ... Jill Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount ... better to eat healthy during the day and even to ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 2014 Each year trauma accounts for ... hospital admissions across the nation (according to the ... CDC’s National Hospital Ambulatory Medical Care Survey collected ... in 2010. They estimated that there were between 3.5 ... a primary diagnosis of broken bone or fracture. ...
Breaking Medicine News(10 mins):Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... Reproductive pressures, dietary preferences all contribute, anthropologist suggests , , ... those extra cavities on their hormones, a new study ... prehistoric and current human populations found that women have ... and fertility issues linked to female-specific hormones. , ...
... blood pressure condition can pose serious threat to woman ... -- Pregnant with her second child, Joan didn,t make ... symptoms worsened. By the time she saw her doctor, ... level, triggering an emergency Caesarean section. , Joan ...
... CALGARY, Oct. 17 /PRNewswire-FirstCall/ - The Westaim ... between its wholly owned,subsidiary iFire Technology Ltd. ... will sell its equipment, patents and intellectual ... The sale is subject to,several conditions, including ...
... Oklahoma Academy of Ophthalmology hosts event October 24 ... OKLAHOMA CITY, Oct. 17 Oklahoma Academy ... benefiting the,Juvenile Diabetes Research Foundation (JDRF) Central Oklahoma ... Sullivan will headline the,event. Lorena and Gary Story ...
... Texas, Oct. 17 When most people go,out to mow ... some spring,cleaning, the last thing they think about is protecting ... October is Eye Injury Prevention Month, and Eye M.D.,s across ... extraordinary,damage often caused by the most ordinary of activities., ...
... Oct. 17 American Well today announced that ... product management;,and Michael Stollar, vice president of marketing ... (HMSA), will provide a live, public,demonstration of Online ... residents,in January 2009. This "Deep Dive Demonstration" will ...
Cached Medicine News:Health News:Hormones May Be to Blame for Women's Cavity Rates 2Health News:Research May Help Predict Preeclampsia 2Health News:Research May Help Predict Preeclampsia 3Health News:Research May Help Predict Preeclampsia 4Health News:Westaim announces sale of iFire Technology Ltd. assets 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 2Health News:Second Annual 'Eye Ball' Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology 3Health News:The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries, Says Texas Ophthalmological Association 2Health News:American Well Systems CEO Roy Schoenberg to Present Live Public Demo of First Online Care Service at Health 2.0 Conference 2
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... First Step Select® Heavy Duty is a pressure ... air loss therapy specifically to the BariKare® Bed., ... 250 and 650 lbs., Large patients at risk ... using a static mattress that would benefit from ...
... Maxxis™ 300 is a healthcare bed system ... individuals in the home care setting, ... combined weight of 2) ,Healthcare frame ... frame size selected, ,CONTRAINDICATIONS: ,Total weight ...
Medicine Products: